Evidence map›Paper›PMID 38561226›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2024

Age-Related Brain Atrophy and the Positive Effects of Behavioral Enrichment in Middle-Aged Beagles.

Jessica A Noche, Hamsanandini Radhakrishnan, Margo F Ubele, Kathy Boaz, Jennifer L Mefford, Erin D Jones, Hollie Y van Rooyen, Jessica A Perpich, Katie McCarty, Beverly Meacham and 9 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 2 countries.

Jessica A NocheUniversity of California, Irvine, California 92697 nochej@uci.edu.ORCID 0009-0001-2182-4151
Hamsanandini RadhakrishnanUniversity of California, Irvine, California 92697.
Margo F UbeleUniversity of Kentucky, Lexington, Kentucky 40506.
Kathy BoazUniversity of Kentucky, Lexington, Kentucky 40506.
Jennifer L MeffordUniversity of Kentucky, Lexington, Kentucky 40506.
Erin D JonesUniversity of Kentucky, Lexington, Kentucky 40506.
Hollie Y van RooyenUniversity of Kentucky, Lexington, Kentucky 40506.
Jessica A PerpichUniversity of Kentucky, Lexington, Kentucky 40506.
Katie McCartyUniversity of Kentucky, Lexington, Kentucky 40506.
Beverly MeachamUniversity of Kentucky, Lexington, Kentucky 40506.
Jeffrey SmileyUniversity of Kentucky, Lexington, Kentucky 40506.
Stasia A Bembenek BaileyUniversity of Kentucky, Lexington, Kentucky 40506.
László G PuskásAperus Pharma, Szeged H-6726, Hungary.
David K PowellUniversity of Kentucky, Lexington, Kentucky 40506.
Lorena SordoUniversity of California, Irvine, California 92697.
Michael J PhelanUniversity of California, Irvine, California 92697.
Christopher M NorrisUniversity of Kentucky, Lexington, Kentucky 40506.
Elizabeth HeadUniversity of California, Irvine, California 92697.
Craig E L StarkUniversity of California, Irvine, California 92697.
University of Kentucky · USUniversity of California, Irvine · USUniversity of Szeged · HU

Funding

University of Kentucky Alzheimer's Disease Research CenterP30AG072946 · NIA · UNIVERSITY OF KENTUCKY · PI LINDA J VAN ELDIK · 2021 to 2026
$23.5M
Preclinical evaluation of tacrolimus in a canine model of Alzheimer's diseaseR01AG056998 · NIA · UNIVERSITY OF KENTUCKY · PI Elizabeth Head, Christopher Mark Norris · 2017 to 2026
$5.3M
Training in Translational ADRD Neuroscience (TITAN)T32AG073088 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Joshua Grill, Elizabeth Head · 2021 to 2026
$2.2M
NIA NIH HHS P30 AG072946NIA NIH HHS R01 AG056998NIA NIH HHS T32 AG073088
6 · The paper itself

Abstract

Aging dogs serve as a valuable preclinical model for Alzheimer's disease (AD) due to their natural age-related development of β-amyloid (Aβ) plaques, human-like metabolism, and large brains that are ideal for studying structural brain aging trajectories from serial neuroimaging. Here we examined the effects of chronic treatment with the calcineurin inhibitor (CNI) tacrolimus or the nuclear factor of activated T cells (NFAT)-inhibiting compound Q134R on age-related canine brain atrophy from a longitudinal study in middle-aged beagles (36 females, 7 males) undergoing behavioral enrichment. Annual MRI was analyzed using modern, automated techniques for region-of-interest-based and voxel-based volumetric assessments. We found that the frontal lobe showed accelerated atrophy with age, while the caudate nucleus remained relatively stable. Remarkably, the hippocampus increased in volume in all dogs. None of these changes were influenced by tacrolimus or Q134R treatment. Our results suggest that behavioral enrichment can prevent atrophy and increase the volume of the hippocampus but does not prevent aging-associated prefrontal cortex atrophy.

Indexed as

AgingAtrophyBrainTacrolimusAnimalsBehavior, AnimalDogsFemaleMagnetic Resonance ImagingMaleTacrolimusAlzheimer's diseaseamyloidbeaglecalcineurinneurodegenerationpreventionQ134Rtacrolimus

Identifiers

PMID38561226
PMCPMC11097262
OpenAlexW4393393457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.